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Abstract 
The response of Mycobacterium tuberculosis to six antimicrobial agents was 
determined by microarray analysis in an attempt to define mechanisms of 
innate resistance in M. tuberculosis. The gene expression profiles of M. 
tuberculosis after treatment at the minimal inhibitory concentration (MIC) for 4 
h with isoniazid, isoxyl, tetrahydrolipstatin, SRI#221, SR1#967 and SR1#9190 
were compared to untreated M. tuberculosis. A common response to drug 
exposure was defined, and this expression profile overlapped with a number 
of other mycobacterial stress responses recently identified by microarray 
analysis. Compound-specific responses were also distinguished including a 
number of putative transcriptional regulators and translocation-related genes. 
These genes may contribute to the intrinsic resistance of M. tuberculosis to 
antimicrobial compounds. Further investigation into these mechanisms may 
elucidate novel pathways contributing to mycobacterial drug resistance and 
influence anti-mycobacterial drug development strategies. 
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Introduction 
In 1993 the World Health Organisation declared tuberculosis (TB) a global 
emergency 1. Ten years on, it has been estimated that the global incidence 
rate of tuberculosis is growing at approximately 0.4%/year 2. Of the world’s 
new tuberculosis cases approximately 3% were attributed to multidrug-
resistant tuberculosis (MDR-TB) in 2000. Although multidrug-resistant 
tuberculosis may not be a problem globally, MDR-TB is at critical levels in 
many hot spots across the world 3. The emergence of MDR-TB, the deadly 
link between TB and HIV infection, the problems of treatment expense and 
patient compliance, and the requirement to eliminate persistent infection 
emphasises the need for new anti-mycobacterial compounds to be developed 
4. 
 
Mechanisms of drug resistance in Mycobacterium tuberculosis have been 
identified to all five first line anti-mycobacterial drugs – isoniazid (INH), 
rifampin, pyrazinamide, ethambutol, and streptomycin. M. tuberculosis 
multiple resistance in these instances is conferred by a series of chromosomal 
mutations 5. However, less is known about mechanisms of intrinsic/natural 
drug resistance in M. tuberculosis such as reduced cell wall permeability, 
efflux systems, or the expression of drug-inactivating enzymes. The poor 
action of many antibiotics, and the relative resistance of bacilli to drying, alkali 
and many chemical disinfectants has often been attributed to the low 
permeability of the unusual cell wall structure of mycobacteria 6. In addition to 
the hydrophobic barrier of the mycobacterial cell wall, several genes encoding 
putative drug efflux systems have been identified in mycobacteria. The 
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probable efflux protein efpA has been reported to be present in slow-growing 
pathogenic mycobacteria 7. The efflux pump LfrA has been demonstrated in 
M. smegmatis to confer low-level resistance to fluoroquinolones 8 and to 
contribute to ethidium bromide resistance 9, whereas the M. tuberculosis P55 
multidrug efflux pump has been identified to confer aminoglycoside and 
tetracycline resistance 10. Indeed, the H37Rv M. tuberculosis genome 
sequencing project revealed the presence of up to 24 members of the major 
facilitator superfamily of transporters, and over 80 putative members of the 
ABC-transporter family 11. Of the ABC-transporter family, 21 export systems 
were defined in M. tuberculosis, many of which are implicated in the export of 
drugs and which may contribute to the innate resistance of mycobacteria to 
broad spectrum antibiotics 12. M. tuberculosis has also been demonstrated to 
express -lactamases 13 and aminoglycoside acetyltransferases 14, which may 
reduce the effectiveness of -lactams and aminoglycosides against M. 
tuberculosis. Further understanding of the mechanisms of intrinsic resistance 
to antibiotic compounds in M. tuberculosis may help to improve existing drug 
treatments and define new drug development strategies. 
 
The advent of microarray technology has allowed the transcriptional profiles of 
bacteria to be examined in response to various stresses. The use of M. 
tuberculosis microarrays was first reported to describe the induction of M. 
tuberculosis genes in response to INH treatment 15. Genes were identified 
encoding proteins related to the mode of action of INH, such as acpM (coding 
for an acyl carrier protein), kasA and kasB (encoding -ketoacyl synthases). 
Other genes most likely involved in the mycobacterial response to the toxicity 
- 5 - 
of the drug were also highlighted – efpA (coding for a putative efflux protein), 
and aphC (alkyl hydroperoxide reductase, involved in the oxidative stress 
response). Microarray analysis of gene expression has also recently been 
used to predict the common functional category of unknown anti-
mycobacterial drugs as part of a pipeline of drug discovery 16. 
 
We describe here the use of a gene-specific M. tuberculosis microarray to 
compare the transcriptional response of M. tuberculosis H37Rv to six 
compounds with anti-mycobacterial activity – (i) INH, a front line anti-
tuberculosis drug targeting mycolic acid synthesis 17; (ii) Isoxyl, a drug used in 
the past to treat tuberculosis, targeting a delta-9 oleic acid desaturase and 
mycolic acid synthesis 18/19; (iii) Tetrahydrolipstatin (THL), a lipase inhibitor 
used in the treatment of obesity 20; and three compounds from The Southern 
Research Institute (Birmingham, Alabama, USA), exhibiting potent anti-
mycobacterial properties (iv) SRI#221; (v) SRI#967; and (vi) SRI#9190. The 
comparison of these six distinct transcriptional profiles defines a common M. 
tuberculosis response to these anti-mycobacterial compounds, and describes 
drug-specific changes which may reflect the mode of action of each drug. This 
investigation also distinguishes genes of unknown function that may 
contribute to the intrinsic resistance of M. tuberculosis to antimicrobial agents. 
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Materials and Methods 
Growth Conditions and RNA Extraction 
Mycobacterium tuberculosis strain H37Rv was grown at 37˚C in Dubos liquid 
medium, supplemented with bacto Dubos medium albumin (Becton 
Dickinson). Mid-log phase mycobacterial cultures were concentrated to 1/20th 
volume of liquid medium and incubated overnight to recover. Antimicrobial 
compounds were added at approximately x1 MIC (determined using the 
Microplate Alamar Blue Assay, MABA 21, at The Southern Research Institute); 
the structures and MICs of the compounds used are detailed in Fig. 1. The 
drug-treated, together with untreated control mycobacterial cultures, were 
incubated at 37˚C for 4 hours. M. tuberculosis RNA was extracted using the 
GTC/TRIzol® method developed by Mangan et al., 1997 22. The RNA samples 
were DNAseI treated and cleaned up on RNeasy® Mini-Columns (Qiagen). 
 
Microarray Hybridisation and Normalisation Strategies 
cDNA derived from three separate RNA extractions for each of the 
compounds tested and from untreated control samples were hybridised to a 
gene-specific PCR product H37Rv M. tuberculosis microarray, the design and 
generation of which is described in Stewart et al., 2002 23. Details of the M. 
tuberculosis microarray used in this investigation can be found at 
http://bugs.sghms.ac.uk/. Two colour competitive hybridisations were 
performed as previously described Stewart et al., 2002 23 hybridising the 
mycobacterial RNA-derived cDNA against M. tuberculosis genomic DNA. The 
hybridised slides were scanned sequentially at 532 nm and 635 nm 
corresponding to Cy3 and Cy5 excitation maxima using the 4.28™ Array 
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Scanner (Affymetrix). Comparative spot intensities from the images were 
calculated using Imagene 4.0 (BioDiscovery), and imported into GeneSpring 
4.2 (Silicon Genetics) for further analysis. The array data was normalised to 
the 50th percentile, and values of less than zero were adjusted to zero. Repeat 
hybridisations using the same cDNA samples (between 3-7 replicates for each 
condition) were replicated together. The experiments were then normalised to 
the untreated control sample using a per gene normalisation strategy. 
 
Microarray Data Analysis 
Two measures of significance were applied to the normalised data set to 
identify differentially regulated genes (i) a minimum p value of 0.05 
incorporating the cross-gene error model (GeneSpring) was set to 
discriminate genes significantly deviating from the 1:1 ratio (treated:untreated) 
which were then subjected to Benjamini and Hochberg correction to take into 
account multiple experiment testing and (ii) a one-way ANOVA (GeneSpring). 
 
A technique of single spot replacement, SSR, (J. Bacon, personal 
communication) was also used to enhance the original data set. The un-
normalised cDNA:genomic DNA ratios for each replicate under each condition 
were imported into Microsoft Excel. For each element on the microarray the 
individual ratio furthest from the median of the replicates was replaced with 
the mean of the remaining ratios. In this way the effect of extreme values was 
minimised from the data set. This SSR data set was then normalised as 
previously described, and subjected to two measures of significance: (i) the 
statistical group comparison (ANOVA); and (ii) the statistical package SAM 
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(Significance Analysis of Microarrays, version 1.15 24) was used to identify 
genes differently expressed in the normalised data sets. A minimum fold 
change of 1.5 between control and drug-treated data sets, and a false 
discovery rate (FDR) of less than one (of the median) was used as a measure 
of significance. 
 
The hypergeometric distribution was used to determine if particular functional 
categories of genes were enriched in response to each drug treatment. The 
hypergeometric p values were calculated as described by Boldrick et al., 2002 
25; where N = 3924 the total number of genes in the population, A = the 
number of genes within each functional classification, x = the number of 
genes identified as up-regulated in response to each drug, and n = the total 
number of genes up-regulated after treatment by each anti-microbial 
compound. 
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Results 
The transcriptional response of M. tuberculosis to each of the six antimicrobial 
agents was defined as the subset of genes identified as significantly 
differentially expressed in two or more statistical tests (described in the 
Methods). Using this analysis strategy, 155 genes were demonstrated to be 
up-regulated by INH treatment (32 down-regulated); Isoxyl (231 up, 21 down); 
Orlistat (208 up, 24 down); SRI#221 (182 up, 25 down); SRI#967 (116 up, 30 
down); and SRI#9190 (124 up, 22 down). The fold changes and predicted 
function of these genes are described as supplementary information Table S1. 
 
Dissecting the transcriptional response of M. tuberculosis to the six drug 
compounds by functional classification (as described by Cole et al., 1998 11) 
revealed that the genes induced by drug treatment broadly represent most of 
the range of pathways that are present in M. tuberculosis. The hypergeometric 
distribution 25 was used to determine whether the enrichment of genes within 
a particular functional category in response to each drug treatment was 
significant (p value < 0.05). Table 1 shows that the number of genes within the 
functional categories of energy metabolism and chaperones/heat shock were 
significantly enhanced after treatment with each of 3 or more anti-microbial 
agents.  The functional category of lipid metabolism was significantly enriched 
in response to INH and isoxyl treatment, as was the category of polyketide 
synthesis after treatment with SRI#967. Additionally, the proportion of genes 
involved in the metabolism of the cell envelope was significantly increased 
after treatment with SRI#221 and SRI#967 (Table 1). 
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Common response to anti-mycobacterial agents 
By comparing the similarities between the M. tuberculosis drug-induced 
expression profiles, a common response to anti-mycobacterial agents could 
be defined. A subset of 80 genes were identified which were significantly up-
regulated after treatment with 3 or more anti-microbial compounds (of a 
maximum 6). These genes are listed in Table 2. Many of these common 
genes induced by exposure to anti-microbial compounds were involved in the 
mycobacterial stress response. Genes associated with DNA repair such as 
end (coding for a probable endonuclease) and recA (encoding recombinase A 
26) were up-regulated; together with Rv3049c (a probable monoxygenase) and 
aphC (alkyl hydroperoxide reductase) expressed in response to oxidative 
stress 27. Also over-expressed after drug treatment (>3 drugs) were gltA1 (a 
probable citrate synthase) and icl (isocitrate lyase) similar to changes in 
metabolism seen under stress conditions 28. RNA polymerase sigma factors A 
and B were also induced, together with serine/threonine protein kinases B and 
G. sigB has been implicated in the M. tuberculosis response to a number of 
stress conditions 29. The product of pknG is predicted to be a soluble protein 
(the transcription of which may be controlled by the redox status of the cell) 
which may be involved in glutamine uptake and which may be up-regulated 
under nitrogen-limiting conditions 30. Additionally the putative nitrate/nitrite 
transporter narK2, the nitroreductase acg and the nitrate reductase narH were 
also identified to be induced. Indeed, five genes demonstrated to be part of 
the ACG (acr-coregulated gene) family were found to be up-regulated after 
exposure to anti-mycobacterial compounds – Rv1733c, narK2, Rv1738, 
Rv2005c, and acg 31. 
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Many of the ‘common’ genes induced by drug treatment have been identified 
as part of the mycobacterial response to other stresses such as low oxygen 
32, heat shock 23, acid shock 33, detergent stress 34, nitric oxide treatment 35, 
phagocytosis 36 or nutrient/carbon starvation 37/Hampshire et al., this issue. 
Those genes, which have also been previously identified to be up-regulated in 
response to these other stresses are marked in Table 2. Of the remaining 
genes induced by 3 or more drugs, five are annotated as efflux proteins or 
transporters – narK2 (a possible nitrate/nitrite transporter), Rv1747 (a 
probable ABC transporter), ctpF (a putative metal cation transporter), efpA (an 
efflux protein), and ctpC (a probable metal cation transporter). A second 
subset of six genes belonging to the ESAT-6 family of proteins was also 
identified as up-regulated after 4 h drug exposure (Rv1037c, Rv1197-Rv1198, 
Rv1793, Rv2346c, and Rv3874). The ESAT-6 gene clusters in M. tuberculosis 
have been associated with the generation and transportation of T-cell 
antigens lacking detectable secretion signals 38. These genes linked to the 
transportation of unknown moieties may be directly involved in the 
mycobacterial response to drug compounds which contributes to the intrinsic 
resistance of mycobacteria to antimicrobial agents. 
 
 
Drug-specific expression responses 
The expression profiles of M. tuberculosis treated with each of the six anti-
microbial compounds were compared, by generating a similarity matrix 
detailing the number of overlapping genes between two drug treatments as a 
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proportion of the possible maximum (Fig. 2). The mycobacterial response to 
INH and isoxyl exposure was most similar as may be expected as both drugs 
target aspects of fatty acid and mycolic acid biosynthesis 17/18/19. The 
expression profiles of M. tuberculosis treated with the compounds SRI#967 
and SRI#9190 were also similar. Aspects of the mycobacterial response to 
individual drugs focusing on the possible action of the compounds is briefly 
presented below. 
 
INH and Isoxyl 
Both INH and isoxyl inhibit fatty acid and mycolic acid biosynthesis in M. 
tuberculosis 17/18/19. INH has been demonstrated to target the enoyl-AcpM 
reductase InhA, a component of the fatty acid synthase – II (FAS-II) 39. Isoxyl 
treatment inhibits mycolic acid and shorter-chain fatty acid synthesis leading 
to the hypothesis that isoxyl may act on other components of FAS-II 18. 
Interestingly, it has also recently been shown to target a delta-9 desaturase in 
mycobacteria 19. Genes coding for enzymes involved in FAS-II were up-
regulated after exposure to both drugs: fabD (coding for a malonyl-CoA::acyl 
carrier protein (ACP) transferase), acpM (an acyl carrier protein), kasA and 
kasB (both -ketoacyl ACP synthases). These have been previously identified 
to be induced by INH, ethionamide and thiolactomycin treatment 15/16. 
Interestingly amongst other fatty acid biosynthetic genes induced by isoxyl 
treatment alone was mabA, a gene coding for a -ketoacyl ACP reductase, 
which also belongs to the FAS-II system. The induction of mabA (which is 
transcriptionally linked to inhA in M. tuberculosis), after exposure to isoxyl, but 
not INH, may reflect differences in the mode of action of these two 
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compounds. Further experiments such as the overexpression of mabA during 
isoxyl exposure may help to elucidate the primary target of isoxyl 40. 
 
Tetrahydrolipstatin 
Tetrahydrolipstatin (THL) is a reversible inhibitor of lipases used in the 
treatment of obesity (Xenical®, Roche). A number of M. tuberculosis putative 
lipases were up-regulated in response to THL treatment – Rv1683, lipD and 
lipV (although this was not significant by hypergeometric testing). Of the 
remaining induced genes, 4 encoding putative transporters (ctpI, sugA, 
Rv3253c, and Rv3781) and 6 coding for probable transcriptional regulators 
were identified (Rv0043c, Rv0823c, sigE, Rv3167c, Rv3687c and Rv3855). 
Also up-regulated on exposure to THL were 4 genes located in a gene cluster 
Rv0676c-Rv0679c. Rv0676c (mmpL5) belongs to a family of conserved large 
membrane proteins, Rv0677c (mmpS5) is part of a related small membrane 
protein family (which appears to overlap stop and start codons with mmpL5), 
the function of Rv0678 is unknown, and Rv0679c codes for a threonine-rich 
protein of undetermined function. The functional significance of this cluster of 
genes in the M. tuberculosis response to THL treatment cannot be elucidated 
by microarray analysis alone. However, further experimentation into this 
cluster or other genes of interest may define novel mechanisms of drug 
resistance in M. tuberculosis. 
 
SRI#221 
Fig. 1 shows that SRI#221 is a potent antitubercular compound with a low 
MIC value, however the primary mode of action of this anti-microbial 
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compound is unknown. Treatment of M. tuberculosis with SRI#221 induced 
two clusters of genes involved in complex lipid biosynthesis. The first cluster 
containing tesA (a probable thioesterase), drrB (an ABC-type transporter), 
papA5 (a polyketide synthase associated protein), and fadD28 (a fatty acid-
CoA ligase), is involved in the biosynthesis and translocation of the multi-
methyl branched mycocerosic acids in the generation of phthiocerol 
dimycocerosates 41. The second gene cluster includes Rv3822 (of unknown 
function), mmpL8 (a conserved large membrane protein), papA1 (a polyketide 
synthase associated protein) and fadD23 (a probable fatty acid-CoA ligase). 
These genes cluster around the polyketide synthase pks2, responsible for the 
biosynthesis of the multi-methyl branched phthioceranic acids present in the 
sulpholipid complex lipids 42. The induction of these gene clusters may be part 
of a compensatory network to minimise the anti-mycobacterial effects of 
SRI#221, may reflect the broad nature of SRI#221 action, or highlight the 
primary mode of SRI#221 action to be within shared basic lipid biosynthetic 
pathways. 
 
SRI#967 and SRI#9190 
The mode of action of the anti-mycobacterial compounds SRI#967 and 
SRI#9190 are yet to be determined. The M. tuberculosis response to SRI#967 
exposure includes the up-regulation of Rv0076c and Rv0077c. Rv0076c 
encodes a probable membrane protein, whereas Rv0077c codes for a 
possible oxidoreductase. Similarly, Rv0135c (a putative transcriptional 
regulator) and Rv0136 (belonging to the cytochrome P450 group of 
monoxygenases) were induced by SRI#9190 treatment alone. The induction 
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of these two distinct clusters (on exposure to different anti-mycobacterial 
compounds) may be part of a similar oxidative stress response. The 
identification that these genes may play a role in the intrinsic resistance of M. 
tuberculosis to anti-microbial agents using microarray analysis enables more 
specific experimental strategies to be employed.  
 
Of particular interest was a cluster of 4 genes which were significantly induced 
on exposure to both SRI#967 and SRI#9190. Rv3159c (encoding PPE53, a 
member of the PPE family), Rv3160c (a putative transcriptional regulator), 
Rv3161c (a probable dioxygenase) and Rv3162c (a possible integral 
membrane protein) were up-regulated on exposure to these compounds alone 
(none of these genes were induced by the other anti-microbial agents tested). 
The probable dioxygenase Rv3161c is most similar to ring hydroxylating 
dioxygenases, so it likely that this enzyme is involved in the degradation of 
benzene ring structures (which SRI#967 and SRI#9190 both contain, Fig. 1). 
Rv3160c and Rv3161c have recently been identified to be induced by 
triclosan treatment 16. Triclosan (2,4,4´-trichloro-2-hydroxydiphenyl ether) 
contains two chlorinated benzene rings. This cluster of genes may therefore 
be induced on exposure to compounds containing halogenated benzene 
rings, this would explain the up-regulation of the cluster in response to 
SRI#967 and SRI#9190, but not to the benzene ring structures in isoxyl and 
SRI#221. This gene cluster may be induced as part of a response to render 
halogenated benzene compounds benign, so contributing to the natural 
resistance of M. tuberculosis to a range of anti-microbial agents. 
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Discussion 
The response of M. tuberculosis to six antimicrobial compounds was 
determined by microarray analysis. The microarray expression data set was 
analysed using several statistical methods, the use of multiple statistical 
methods added extra depth to the interpretation of the data sets. Additionally, 
a single spot replacement strategy was used alongside the original data set to 
allow the maximum amount of information to be extracted from the data sets 
without significantly shifting the expression patterns. 
 
Using this microarray analysis strategy, elements of a M. tuberculosis 
common stress response and specific drug-induced changes were identified 
to six antimicrobial compounds. The up-regulation of genes specific to each 
compound may reflect the mode of action of the drug or define innate 
resistance mechanisms in M. tuberculosis. This investigation has defined an 
initial subset of genes which may be important in the innate resistance of M. 
tuberculosis to antimicrobial agents. Microarray profiling of M. tuberculosis 
gene expression after exposure to drugs enables compounds of unknown 
mechanism of action to be classified into similarity groups, but in this study 
has not been helpful to elucidate the site of or mechanism of action. This 
would require complementary genetic and biochemical studies informed by 
microarray profiling. 
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Figure 1 – The structures of the antimicrobial compounds used in this 
investigation. The source and the approximate MIC of the compounds against 
M. tuberculosis are also detailed. MICs were determined using the Microplate 
Alamar Blue Assay (MABA) 21 at The Southern Research Institute 
(Birmingham, Alabama, USA). 
 
Figure 2 – A similarity matrix comparing the genes up-regulated in response 
to the 6 anti-microbial compounds tested (isoniazid, INH; isoxyl, ISO; 
tetrahydrolipstatin, THL; SRI#221/967/9190). Numbers in the top half of the 
figure represent the number of common genes up-regulated in response to 
two compounds. The maximum number of genes identified as significantly up-
regulated (in more than 2 statistical tests) after treatment with each drug are 
displayed in the shaded cells. The bottom half of the matrix describes the 
number of genes common to two drug responses as a proportion of the 
possible maximum, calculated as 1-(common genes/maximum possible 
genes). The smaller this proportion is the greater the extent of the overlap 
between expression responses. 
 
Table 1 – The M. tuberculosis response to 6 anti-microbial compounds 
examined by functional category, as defined by Cole et al., 1998 11. Only 
genes identified as significantly over-expressed in two or more of the 
statistical tests described in response to isoniazid (INH), isoxyl (ISO), 
tetrahydrolipstatin (THL), SRI#221/967/9190 are detailed in these tables. 
These gene lists are described in Supplementary Table S1. The 
hypergeometric probabilities 25 of the enrichment of particular functional 
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categories of genes in response to each drug treatment are indicated if a p 
value < 0.05, b < 0.01, c < 0.001. 
 
Table 2 – The common response of M. tuberculosis to 6 anti-microbial agents, 
detailing the genes identified to be up-regulated in response to 3 or more of 
the anti-microbial compounds tested (maximum 6). Numbers in the columns 
(INH isoniazid, ISO isoxyl, THL tetrahydrolipstatin, SRI# 221/967/9190) 
indicate the number of statistical tests in which each gene was found to be 
significantly induced (minimum of 2, maximum 4). The left column labelled N 
details the number of drugs in which each gene was significantly differentially 
expressed. Dots present in the columns A-J indicate that the gene has been 
previously identified to be up-regulated in response to various other stresses; 
A INH treatment 15, B INH and TLM treatment 16, C low oxygen 32, D nutrient 
starvation 37, E nitric oxide treatment 35, F phagocytosis 36, G carbon 
starvation (Hampshire et al., this issue), H detergent stress 34, I heat shock 23, 
J acid shock 33. This table is ordered by Rv number. 
 
Supplementary Data Table S1 – The differentially regulated genes in 
response to 6 anti-microbial compounds. These tables describe the genes 
identified as significantly differentially expressed in the M. tuberculosis 
responses to each of the six anti-microbial compounds tested. Each table 
consists of the gene name (and unique gene identifier), Rv number, a brief 
description of the proposed function of the gene and the fold expression ratios 
determined using each of the four statistical tests described. The number of 
times each gene has been identified as significantly differentially expressed is 
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detailed in the column labelled N. Cells in this column coloured purple indicate 
the presence of consecutive Rv numbers. Only genes identified by two or 
more statistical tests have been included in these tables. These tables are 
ordered by Rv number. 
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Figure 1 
Structure of Drug Compound Tested 
Approximate 
MIC 
Source 
Isoniazid 
0.2 µg/mL 
Sigma 
I-3377 
Isoxyl 
2 µg/mL NIMR, UK 
Tetrahydrolipstatin 
50 µg/mL 
Hoffmann-
La Roche 
SRI#221 
0.4 µg/mL SRI, USA 
SRI#967 
6.25 µg/mL SRI, USA 
SRI#9190 
6.25 µg/mL SRI, USA 
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Table 1 
Functional Classification (as defined by Cole et al., 1998 11) 
Genes identified as up-regulated 
INH ISO THL 221 967 9190 
I. Small-molecule Metabolism       
  A. Degradation (163) 8 8 8 5 8 7 
  B. Energy Metabolism (292) 10 32c 18 18a 9 14a 
  C. Central Intermediary Metabolism (45) 3 3 1 4  1 
  D. Amino Acid Biosynthesis (95) 4 7 1 2 2 2 
  E. Polyamine Synthesis (1)       
  F. Purines, Pyrimidines, Nucleosides and Nucleotides (60) 2 2  5   
  G. Biosynthesis of Cofactors, Prosthetic Groups and Carriers (117) 5 2 4 7 2 3 
  H. Lipid Biosynthesis (65) 7b 11c 4 5 3 3 
  I. Polyketide and Non-Ribosomal Peptide Synthesis (41) 4 3 2 3 4a 2 
  J. Broad Regulatory Functions (187) 4 5 7 9 8 5 
II. Macromolecule Metabolism       
  A. Synthesis and Modification of Macromolecules (215) 10 17a 17a 12 8 10 
  B. Degradation of Macromolecules (87) 3 7 5 5 1 2 
  C. Cell Envelope (360) 16 23 18 26b 20b 9 
III. Cell Processes       
  A. Transport/Binding Proteins (123) 7 7 9 4 1 3 
  B. Chaperones/Heat Shock (16) 3a 6c 3a 1  3a 
  C. Cell Division (19)  2 3 1   
  D. Protein and Peptide Secretion (14)  2 1 1  1 
  E. Adaptations and Atypical Conditions (12)     1  
  F. Detoxification (22)  1 1 3 1 1 
IV. Other       
  A. Virulence (38)   1 1 1  
  B. IS Elements, Repeated Sequences and Phage (135) 9a 1 11a 1 3  
  C. PE and PPE Families (167) 10 6 9 2  4 
  D. Antibiotic Production and Resistance (14)   1 1  1 
  E. Bacteriocin-like Proteins (3)    1   
  F. Cytochrome P450 Enzymes (22) 1 1 2 3 1 1 
  G. Coenzyme F420-dependent Enzymes (3)  1     
  H. Miscellaneous Transferases (61) 1 3 4 2 3 2 
  I. Miscellaneous Phosphatases, Lyases and Hydrolases (18)      1 
  J. Cyclases (6)   1 1   
  K. Chelatases (2)       
V. Conserved Hypotheticals (915) 36 61 40 26 29 30 
VI. Unknowns (606) 12 20 37 33 11 19 
Total Genes (3924)       
Total up-regulated genes after drug treatment 155 231 208 182 116 124 
Percentage of unknown function (39% of total genes unknown) 31 35 37 32 34 40 
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Figure 2 
  INH ISO THL #221 #967 #9190 
INH 155 67 27 19 24 30 
ISO 0.568 231 44 36 39 44 
THL 0.826 0.788 208 32 29 25 
#221 0.877 0.802 0.824 182 36 30 
#967 0.793 0.664 0.750 0.690 116 44 
#9190 0.758 0.645 0.798 0.758 0.621 124 
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Table 2 
 
N Gene Name Rv No INH ISO THL 221 967 9190 Putative Function A B C D E F G H I J 
3 pknB Rv0014c    2 3 3 Serine/threonine protein kinase B        •   
4 rpsF Rv0053  2  2 3 3 Ribosomal protein S6   •        
5 icd2 Rv0066c  2 2 3 3 3 Isocitrate dehydrogenase   •     •   
3 fbpC2 Rv0129c  4 2   3 Antigen 85c, mycolyl transferase C •   •       
4 pntAB Rv0156 2 3 2 3   Probable NAD(P) transhydrogenase           
4 bglS Rv0186 2 2   2 3 Probable beta-glucosidase        •   
4 Rv0247c Rv0247c  2 3  3 2 Probable succinate dehydrogenase           
3 fadD2 Rv0270 4  2   2 Probable long-chain fatty acid CoA ligase           
3 Rv0349 Rv0349 2  2 3   Unknown           
3 pknG Rv0410c  2 2 2   Serine/threoine protein kinase G   •        
3 Rv0412c Rv0412c 2 2  2   Possible conserved membrane protein   •    •    
3 Rv0446c Rv0446c  3  2 2  Possible conserved membrane protein      •     
3 icl Rv0467 4 2    2 Isocitrate lyase      • • •  • 
3 mmpS2 Rv0506    2 2 3 Unknown, probable membrane protein           
3 end Rv0670 2 2    2 Probable endonuclease IV   • •   •    
4 rpsS Rv0705  2 2  3 4 30s ribosomal protein s19           
4 rpmC Rv0709  3 2  2 4 50s ribosomal protein L29           
3 rplR Rv0720 4 2    2 50s ribosomal protein L18           
3 Rv0851c Rv0851c    2 2 2 Probable dehydrogenase/reductase      •     
4 fadE10 Rv0873 4 4 2  2  Probable acyl-CoA dehydrogenase       • •   
3 Rv0910 Rv0910  2 2 2   Unknown           
3 sucC Rv0951 3 3 2    Probable succinyl-CoA synthetase  •         
4 esxI Rv1037c 4 3   3 3 Putative ESAT-6 like protein        •   
5 Rv1109c Rv1109c 2 3  3 3 2 Unknown       •    
3 gltA1 Rv1131 4 2 2    Probable citrate synthase      • • •  • 
4 narH Rv1162 2 2  2  2 Probable respiratory nitrate reductase   •     •   
3 papA3 Rv1182   3  3 3 Polyketide associated protein    •     •  
3 Rv1184c Rv1184c  2 3  3  Unknown, possible exported protein      •     
4 esxK Rv1197 3 2   3 3 Putative ESAT-6 like protein           
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4 esxL Rv1198 4 4   2 4 Putative ESAT-6 like protein           
3 atpG Rv1309  2 2 2   ATP synthase gamma chain           
3 PPE19 Rv1361c 4 4   2  PPE family protein           
4 appC Rv1623c 2 2  3  3 Probable cytochrome D ubiquinol oxidase           
4 Rv1683 Rv1683 2  2  2 2 Possible long-chain acyl-CoA synthase   •        
4 Rv1733c Rv1733c 4 4   3 4 Probable conserved transmembrane protein   •  • •     
3 narK2 Rv1737c 4 3 2    Possible nitrate/nitrite transporter   •  • •     
4 Rv1738 Rv1738  4  2 2 3 Unknown   •  • •   •  
3 Rv1747 Rv1747  2 2  2  Probable membrane transport protein           
4 esxN Rv1793 3 3   3 3 Putative ESAT-6-like protein           
4 Rv1813c Rv1813c 2 4 2   2 Unknown   •  • •     
4 Rv1987 Rv1987 3  4 3 3  Probable chitinase  •  •       
3 ctpF Rv1997  2 2   2 Probable metal cation transporter   •  • •     
4 Rv1998c Rv1998c  2 2  2 2 Unknown   •  •      
3 Rv2005c Rv2005c 4 4 2    Unknown   •  • •   •  
3 fdxA Rv2007c 2 4    2 Probable ferredoxin  • •  • •   • • 
6 acg Rv2032 3 4 2 3 3 4 Unknown, possible nitroreductase   •  • •     
4 Rv2091c Rv2091c  3  2 3 4 Unknown, probable membrane protein    •   •    
3 Rv2147c Rv2147c  3 2   3 Unknown protein           
3 Rv2185c Rv2185c  2  2  2 Unknown (TB16.3)    •     •  
5 cbhK Rv2202c 3 3 2  2 3 Probable carbohydrate kinase        •   
4 fabD Rv2243 2 4 2 3   Malonyl CoA-acyl carrier transacylase • • •        
5 acpM Rv2244 4 4  4 3 3 Meromycolate extension acyl carrier protein • • •        
4 kasA Rv2245 2 2  2 2  Beta-ketoacyl-ACP synthase • •  •       
3 htpG Rv2299c  4 3 3   Probable heat shock protein         •  
4 esxO Rv2346c 3 3   2 4 Putative ESAT-6 like protein           
3 Rv2405 Rv2405 2 2  3   Unknown    •       
3 ahpC Rv2428   3 4 3  Alkyl hydroperoxide reductase C • • •   •    • 
4 pepD Rv2467 3 4 2  3  Probable aminopeptidase (pepN)           
5 Rv2626c Rv2626c 3  2 2 2 2 Unknown   •  • •     
3 Rv2627c Rv2627c  4  2 2  Unknown   •  • •     
3 Rv2629 Rv2629   2 2  2 Unknown   •  • •     
3 sigA Rv2703    3 2 3 RNA polymerase sigma factor A        •   
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4 sigB Rv2710 3  2 2  4 RNA polymerase sigma factor B    •  • • • •  
3 recA Rv2737c  2 2   3 Recombinase A protein           
6 35kd_ag Rv2744c 2 2 2 2 2 3 35-kd alanine rich antigen       • • • •  
4 thyX Rv2754c  2  2 2 3 Probable thymidylate synthase           
3 Rv2818c Rv2818c   3 4 3  Unknown           
3 efpA Rv2846c 4 4 2    Putative efflux protein • •         
3 Rv2959c Rv2959c  2 2 3   Possible methyltransferase           
5 Rv3049c Rv3049c  2 2 2 2 2 Probable monoxygenase           
3 PPE51 Rv3136 4 2    2 PPE family protein   •        
3 rubB Rv3250c 3 3    2 Probable rubredoxin      •     
3 ctpC Rv3270  2 2   2 Probable metal cation transporter   •    •    
3 PE_PGRS52 Rv3388 2 2   2  PE_PGRS family protein           
3 PPE60 Rv3478 4 4 2    PPE family protein           
3 Rv3592 Rv3592 3 3   2  Unknown (TB11.2)       •    
4 panD Rv3601c 2   2 2 4 Aspartate1-decarboxylase           
3 mmpL8 Rv3823c    2 2 2 Conserved large membrane protein           
3 papA1 Rv3824c    2 2 2 Polyketide associated protein    •    •   
5 esxB Rv3874  2 2 2 2 2 10 KDa culture filtrate antigen (cfp10)           
 
 
